Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

Martin Dreyling, Andre Goy, Georg Hess, Brad S. Kahl, José Ángel Hernández-Rivas, Natasha Schuier, Keqin Qi, Sanjay Deshpande, Angeline Zhu, Lori Parisi, Michael L. Wang

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)E712
JournalHemaSphere
Volume6
Issue number5
DOIs
StatePublished - May 13 2022

Cite this